Retatrutide Side Effects: 42% Nausea, 15% on Placebo

Retatrutide (LY-3437943) is a triple agonist for GLP-1, GIP and glucagon receptors in clinical development. For tolerability, the published Phase 2 study and the TRIUMPH-4 results - so far available only as a topline announcement - are most relevant. This article summarises the available safety data from both sources and flags where statements remain preliminary.

For a comprehensive overview of the peptide itself, see our main article: Buy Retatrutide: The Triple Agonist in GLP-1 Research.

What is Retatrutide? A Brief Overview

Retatrutide is a synthetic peptide developed by Eli Lilly that simultaneously activates three incretin and metabolic receptors:

• GLP-1 (Glucagon-like Peptide-1): appetite regulation and insulin secretion
• GIP (Glucose-dependent Insulinotropic Polypeptide): insulin sensitivity and fat metabolism
• Glucagon: energy expenditure, lipolysis and thermogenesis

This mechanism distinguishes retatrutide from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). Whether and to what extent the additional glucagon receptor activation influences specific side effects is the subject of ongoing research.

Gastrointestinal Side Effects: The Most Common Category

As with other incretin-based peptides, gastrointestinal (GI) side effects dominate the safety profile of retatrutide. The most frequently reported GI effects are nausea, diarrhoea, vomiting and constipation.

Phase 2 Data (NEJM 2023, Jastreboff et al., PMID 37366315, NCT04881760)

The Phase 2 obesity study enrolled 338 participants over 48 weeks. The published analysis examined 1 mg, 4 mg, 8 mg and 12 mg, with the 4 mg and 8 mg arms each reported with different starting doses. The overall rate of adverse events ranged from 73% to 94% in the retatrutide cohorts, compared to 70% under placebo. Most of these events were mild to moderate.

The Phase 2 data point to two patterns. First, the gastrointestinal events were dose-related. Second, the relationship is not driven by the target dose alone: the publication states the events "were partially mitigated with a lower starting dose", so at the same target dose the starting point mattered. Note the limit of that claim: it establishes that the starting dose made a difference, not that escalation speed as such drives tolerability.

The rate of serious adverse events was reported at 4% in both groups (retatrutide and placebo). Read that similarity carefully: the trial was sized to detect weight outcomes, not uncommon harms, so equal serious-event rates at this sample size are not evidence that severe complications do not occur.

Phase 3 Data (TRIUMPH-1, 2,339 Participants)

TRIUMPH-1 is the largest safety dataset for retatrutide to date: 2,339 participants, randomised to 4 mg, 9 mg, 12 mg or placebo, with an 80-week main phase. The figures come from Eli Lilly's topline announcement and are not peer-reviewed.

The decisive difference from every other table in this article: here there is a placebo column.

This column changes the reading considerably. Nausea also occurred at 14.8% under placebo, constipation at 10.9%. A meaningful share of the reported complaints is therefore not substance-specific and turns up even without active drug. Anyone who looks only at the 42.4% overestimates the effect.

The case is different for dysaesthesia: 0.9% under placebo against 12.5% at 12 mg. That is a clear, dose-dependent signal. Dysaesthesia and urinary tract infections were described as mostly mild to moderate, and most resolved during treatment.

Discontinuations Due to Side Effects in TRIUMPH-1

At 4 mg the discontinuation rate is below that of placebo; at 12 mg it is more than double. The announcement does not report rates for serious adverse events, and that gap remains open.

Phase 3 Data (TRIUMPH-4, December 2025)

The TRIUMPH-4 study examined 445 adults over 68 weeks at maintenance doses of 9 mg and 12 mg. To date, only topline data from Lilly are available, not a full peer-reviewed publication. GI side effects were reported separately for each dose:

Compared to Phase 2, some individual rates are lower, others are not. An optimised dose escalation schedule is a plausible contributing factor, but no reliable causal conclusion can be drawn from the available topline data.

Meals as a Trigger: Fat Load, Gastric Emptying and What the Trials Did Not Record

The tables above count events by dose arm; the search below documents what the trials recorded. Community reports on r/Retatrutide and r/tirzepatidecompound describe a recurring shape: a fried or rich meal, then severe abdominal pain hours later, often overnight, with vomiting or diarrhea. That is a community report, not a scientific sample. The mechanism half is answerable from published work; an off-limits-food list is not, and neither is whether to hold a dose afterwards, which is a clinical decision.

On the drug side, the finding for investigational retatrutide is a Lilly report's title: "The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying" (PMID 37311727). For the approved dual agonist tirzepatide, a phase 1 study reported delayed gastric emptying in its single-dose comparison and a residual delay after multiple doses in participants with type 2 diabetes on the 5/5/10/10 mg and 5/5/10/15 mg escalation schedules (PMID 32519795).

On the meal side, the physiology predates these compounds: those studies varied the fat load, not the dish. In thirteen healthy men, intraduodenal lauric acid at 0.1, 0.2 and 0.4 kcal/min dose-dependently stimulated isolated pyloric pressure waves, decreased antral and duodenal motility, and stimulated secretion of CCK and GLP-1 (PMID 15961531). Sixteen healthy men received a 120-minute duodenal triglyceride infusion at 2.8 kcal/min; lipase inhibition reduced tonic and phasic pyloric pressures, abolished the rises in plasma CCK and GLP-1, and left nausea scores slightly lower (PMID 12684211). The lauric-acid study infused fat into the duodenum rather than serving a meal (PMID 15961531). The triglyceride study did the same (PMID 12684211). Inferring an episode hours later from either result goes beyond the measured endpoints.

As of 2026-09-04, no completed study has reported meal composition tested as a trigger for gastrointestinal adverse events under investigational retatrutide or approved tirzepatide (PubMed search: "(retatrutide OR tirzepatide) AND (meal composition OR dietary fat OR high-fat meal OR fatty meal) AND (gastrointestinal adverse OR nausea OR vomiting)"; ClinicalTrials.gov search: "tirzepatide AND (dietary fat OR fatty meal OR meal composition) AND gastrointestinal"). One uncontrolled real-world series of 219 Japanese patients on tirzepatide reports discontinuation due to gastrointestinal adverse events; dietary questionnaires indicated reduced appetite for high-fat and high-calorie foods, which the authors say "may have contributed" (PMID 41462404). That is a tirzepatide observation, not a retatrutide comparator. A Mayo Clinic Proceedings review for primary care physicians discusses diet-based symptom management for patients on approved drugs (PMID 41324524). It is clinical guidance, not evidence from a meal-trigger trial.

Dose Escalation and Starting Dose

The starting dose influences the tolerability of retatrutide. The Phase 2 study ran the 4 mg and 8 mg targets with different starting doses, and the publication states that the gastrointestinal events "were partially mitigated with a lower starting dose" (PMID 37366315). Participants who reached 8 mg starting from 4 mg showed higher GI event rates than those escalating from a lower start. What the publication supports is the effect of the starting dose; it does not isolate escalation speed as a separate causal factor.

In TRIUMPH-4, Lilly reports that the dose was titrated in four-week steps from 2 mg up to the 9 mg or 12 mg maintenance dose (topline data, not peer-reviewed).

When Do the Side Effects Subside?

In the Phase 2 study, GI side effects occurred particularly during the escalation phase and diminished thereafter. In TRIUMPH-1, dysaesthesia and urinary tract infections were described as mostly mild to moderate, and most resolved during treatment. None of the available publications names a specific week from which the complaints disappear.

For research, this finding is relevant: dose escalation protocols are a central factor in study design with retatrutide and comparable peptides.

Dysaesthesia: A New Safety Signal

TRIUMPH-4 reports dysaesthesia as a notable sensory side effect. This refers to an altered skin sensation in which normal touch is perceived as unusual or unpleasant.

This signal was not described with the same prominence in the Phase 2 study, although reports of cutaneous hyperaesthesia and skin sensitivity were present there (approximately 7% under retatrutide vs. 1% under placebo).

No reliable mechanistic explanation for dysaesthesia has been published from the available data. Lilly stated that dysaesthesia events were mild and rarely led to discontinuation, which is not the same as saying they did not affect discontinuation at all. More detailed data on severity, duration and body regions affected are still outstanding.

Headache: What the Registry Tables Report

In the phase 2 obesity trial (NCT04881760), headache was recorded in 0 of 70 on placebo, 2 of 69 at 1 mg, 1 of 33 and 0 of 33 in the two 4 mg arms, 0 of 35 and 4 of 35 in the two 8 mg arms, and 4 of 62 at 12 mg (paired arms differ in starting dose). No migraine term appears, so none reached 5 percent. The phase 2 diabetes trial (NCT04867785) posted 2 of 45 on placebo and, across the retatrutide arms, between 1 of 46 at 12 mg and 3 of 26 at 8 mg.

A meta-analysis of three placebo-controlled retatrutide trials (640 patients, 510 on retatrutide) pooled headache at RR 1.75 (95% CI 0.34 to 9.14, I squared 24 percent), too imprecise to separate from no effect (PMID 39318607). At trial level that is the dose answer; whether one person's headaches track their dose is beyond these designs. TRIUMPH-1 (NCT05929066), the largest completed trial, has posted no results in the registry.

For the approved class, where labels and pharmacovigilance exist:

• WEGOVY (semaglutide) adult label: headache 14 percent on 2.4 mg (N=2,116) vs. 10 percent on placebo (N=1,261).
• Its 7.2 mg table: headache 7 percent on placebo, 8 percent at 2.4 mg and 9 percent at 7.2 mg, while nausea runs 13, 35 and 39 percent.
• ZEPBOUND (tirzepatide): its table of reactions at 2 percent or more and above placebo has no headache row.
• FAERS disproportionality across 25,110 neuropsychiatric reports: headache reporting odds ratio 1.74 (95% CI 1.65 to 1.84), migraine 1.28 (1.06 to 1.55), which the authors call exploratory (PMID 39901452). Retatrutide, holding no marketing authorization, appears nowhere in that report's drug set; more rows: our sleep and mood article.

For context, the semaglutide label documents that gastrointestinal reactions leading to dehydration preceded most post-marketing acute kidney injury reports. Whether a given headache is drug-related is a clinical question, not one these tables settle.

Heart Rate

The Phase 2 study measured this, and part of the magnitude is traceable to sources a reader can open. Change in heart rate and blood pressure from baseline to weeks 24 and 36, assessed by 24-hour ambulatory monitoring, was a prespecified exploratory endpoint, and heart rate was also recorded through week 48.

At week 48, heart rate was 6.0 bpm above baseline at 12 mg against 0.4 bpm under placebo, with a clean dose gradient below that: 1.7 bpm at 1 mg, 3.1 bpm at 4 mg and 4.8 bpm at 8 mg. Those figures are not printed in the publication's main text; they are retrievable from the open-access 2026 systematic review that tabulated the trial arm by arm (Zhang et al., European Journal of Medical Research, PMID 41582189), and the 4 mg and 8 mg values are that review's pooling of the two starting-dose arms the trial ran at each of those doses. The shape of the effect is described by the publication rather than numbered in its main text: the heart rate increased in a dose-dependent manner, peaked at 24 weeks and then declined at 36 and 48 weeks, and the publication notes the increases were similar to those reported for GLP-1 receptor agonists.

The per-timepoint ambulatory tables sit in a supplementary appendix that is not publicly accessible, so we quote no week-24 or week-36 figure. The same applies to the blood-pressure counterpart: what the publication states in text is that treatment was associated with improvements in cardiometabolic measures including systolic and diastolic blood pressure, glucose, insulin and lipids, with the exception of HDL cholesterol, and that these improvements led to discontinuation of at least one antihypertensive medication in 41% of the combined 8 mg group and 30% of the 12 mg group. Reporting the heart-rate increase without that counterpart would misrepresent the trial.

Heart-rate increases are a known effect across incretin agonists and are monitored clinically. The full picture, including how these figures compare with tirzepatide and semaglutide and what is and is not known about heart-rate variability, is covered in Retatrutide, Heart Rate and HRV.

Ketone Odor, Frequent Urination and Night-Time Thirst: Forum Reports With No Trial Endpoint

The tables above count what the protocols asked about. Three themes in r/Retatrutide fall outside them: sweat or breath smelling of acetone or ammonia (in 2 posts), a night of constant urination after an injection (in 3 posts), and waking hot and thirsty (in 4 posts). No post carries all three.

The glucagon arm named at the top of this article is the hook. A post-hoc metabolomics analysis of both phase 2 trials, 282 obesity and 213 type 2 diabetes participants, found that higher doses of retatrutide were associated with changes in a cluster of metabolites comprising 3-hydroxybutyrate, acetylcarnitine, free carnitine and fatty acid-derived long-chain acylcarnitines (PMID 42135195). Mediation analyses suggested that changes in those biomarkers mediated 23.2% of the weight-reduction response in participants without type 2 diabetes, blunted to 12.7% in those with it (PMID 42135195). Ketone bodies are 3-hydroxybutyrate, acetoacetate and acetone (PMID 32525972). In 35 participants with diabetes, breath acetone correlated with blood total ketone bodies at R = 0.828 (PMID 35868249).

Sweat is a poor readout of that. A review of eccrine sweat composition, which covers ammonia and urea among sweat metabolites, states that correlations between sweat and blood have not been established for most constituents and that sweat metabolite concentrations are not a reliable biomarker for exercise intensity or other physiological stressors (PMID 32124007).

The posted phase 2 obesity adverse-event table lists non-serious terms at a 5% reporting threshold, urinary tract infection among them, and no polyuria, nocturia, thirst or hyperhidrosis entry (NCT04881760). As of 2026-09-04, no completed study has reported breath or sweat acetone, sweat ammonia, polyuria, nocturia or thirst under retatrutide, and none has reported ketone measurements beyond the analysis above (PubMed search: "retatrutide AND (acetone OR sweat OR ammonia OR polyuria OR nocturia OR thirst)" and "retatrutide AND (ketone OR ketosis OR acetone OR beta-hydroxybutyrate)"; ClinicalTrials.gov search: the same two strings). The nearest measurements sit in two completed sponsor trials, neither with results posted. A phase 2b renal study lists creatinine-corrected fractional urinary sodium excretion and 24-hour urinary electrolytes as secondary outcomes (NCT05936151, 146 participants, completed October 2025). A phase 1 study lists sleep metabolic rate and 24-hour energy expenditure (NCT06313528, 85 participants, completed August 2025). Night-time waking sits in our sleep review.

The ketone search returns that analysis and one case report: a man in his mid-30s with type 1 diabetes and Shigella gastroenteritis presented with severe vomiting, diarrhea, hyperglycemia, ketonemia and acute kidney injury after self-administering an online-purchased product marketed as retatrutide, peak ketonemia reached 4.3 mmol/L with dehydration and insulin omission, requiring intravenous insulin and fluid replacement, and the author states that causation cannot be established (PMID 42669023). The case measures blood ketones, not breath or sweat.

Chills, Sore Throat and Running Hot: What the Trial Tables Contain

Community threads describe a cluster with no row in the tables above: sore throat, aching limbs, night sweats or chills after an injection, cold legs one day and running hot the next.

In the phase 2 obesity trial's posted results (NCT04881760, enrollment 338), non-serious adverse events were tabulated at a threshold of 5 percent or more in any treatment group, and the posted term list carries no entry for chills, pyrexia, influenza-like illness, myalgia, hyperhidrosis or hot flushes. What it does carry in that direction is four infection terms: nasopharyngitis, sinusitis, upper respiratory tract infection and COVID-19. None of them shows the dose gradient the gastrointestinal rows do: nasopharyngitis 3 of 70 in the placebo arm against 0 of 62 at 12 mg, upper respiratory tract infection 2 of 70 against 2 of 62, COVID-19 14 of 70 against 15 of 62. The phase 2 diabetes trial's record (NCT04867785, enrollment 281) carries the same 5 percent threshold, the same four infection terms and no thermal term either. The TRIUMPH-1 sponsor topline row above sits near its placebo column.

These tables record what investigators coded, not what participants felt, and the obesity trial counts events from baseline through end of safety follow-up, up to 52 weeks (NCT04881760), so they cannot show clustering in the hours after a dose.

As of 2026-09-04, no completed study has reported chills, fever-like episodes, night sweats or excessive sweating as an adverse event of investigational retatrutide (PubMed search: 'retatrutide AND (chills OR pyrexia OR fever OR "flu-like" OR "influenza-like" OR "night sweats" OR hyperhidrosis)', one record, a dermatology review that lists hyperhidrosis for the GLP-1 class and not for retatrutide, PMID 42562129; ClinicalTrials.gov search: the same term string, no studies). As of 2026-09-04, no completed study has reported body-temperature or thermoregulation outcomes for retatrutide (PubMed search: 'retatrutide AND (thermoregulation OR "body temperature" OR chills OR hyperhidrosis OR "hot flush" OR "cold intolerance" OR sweating)', one hit, the same review; ClinicalTrials.gov search: intervention "retatrutide", 33 studies, outcome measures screened for temperature and calorimetry terms).

The mechanism literature is narrower:

• The closest human measurement is unpublished: NCT06313528, a completed phase 1 trial with enrollment 85, carried 24-hour energy expenditure and sleep metabolic rate as secondary outcomes, with no results posted.
• What is public is preclinical: in obese mice, body weight loss under LY3437943 was augmented by GCGR-mediated increases in energy expenditure added to GIPR- and GLP-1R-driven calorie intake reduction (PMID 35985340).
• In 11 healthy male volunteers, a glucagon infusion at 50 ng/kg/min raised energy expenditure by 15 percent against 14 percent for cold exposure, without altering neck temperature (PMID 26434748).
• The energy deficit alone moves temperature: in a randomized 6-month trial of 48 overweight adults with no drug involved, core body temperature fell in the two calorie-restriction arms (PMID 16595757).
• The DailyMed label for Zepbound (tirzepatide, SPL version dated 28 August 2026) carries no temperature-related adverse reaction and names sweating only in its low-blood-sugar sign list. The Wegovy label (semaglutide, SPL version dated 18 June 2026) reads the same way. Investigational retatrutide has no counterpart to set beside those two: a Drugs@FDA query for a retatrutide product returns no match.

The thermoregulation cluster in AI Reads 400,000 Reddit Posts was mined from posts on semaglutide, tirzepatide, liraglutide and related compounds rather than a retatrutide cohort, and names cold sensitivity, chills, hot flushes and fever-like sensations over weeks of fat loss, not sore throat, body aches or night sweats.

Whether an episode is infection, an uncoded drug effect or coincidence is a clinician's question, not a trial-table one.

Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide

This article previously carried a table of side-by-side adverse-event percentages for semaglutide (STEP-1), tirzepatide (SURMOUNT-1) and retatrutide. We have removed it, and the reason is worth stating plainly.

No head-to-head trial of retatrutide against semaglutide or tirzepatide exists. Every number in such a table therefore comes from a different trial, in a different population, with a different escalation schedule, a different duration and different reporting conventions. Lining those columns up implies a comparison the underlying data cannot support.

Worse, when we went back to re-verify the individual percentages against the primary publications, we could not confirm several of them from the sources we can actually read: the per-dose adverse-event rates for the comparator trials sit in full-text supplements rather than in the abstracts, and at least one figure we had published appears to have been materially off. Rather than keep numbers we cannot stand behind and label them "indicative", we took them out.

What can be said honestly is narrower:

• All three compounds are dominated by gastrointestinal adverse events, and in all three those events scale with dose. This is the consistent finding across the programmes.
• Retatrutide adds glucagon-receptor activity that the other two do not have (tirzepatide has two targets, semaglutide one), which is a plausible reason to expect its profile is not simply a scaled version of theirs, but that is a mechanistic expectation and not a measured comparison.
• Dysaesthesia appears in the retatrutide reporting and does not appear in the semaglutide or tirzepatide weight-management reports. Whether that reflects a real difference between the compounds, or a difference in how and what these trials reported, is not established by the data available.

Anyone who shows you a clean cross-trial safety ranking of these three is showing you an artefact of trial design, not a finding.

Discontinuation Rates as a Tolerability Indicator

The study discontinuation rate due to side effects provides guidance on the overall tolerability of a peptide.

Lilly noted that some discontinuations in TRIUMPH-4 were attributed to weight loss perceived as too rapid and not necessarily to classic intolerance. Without a full publication, complete interpretation of these discontinuations remains limited. Participants with higher BMI showed lower discontinuation rates according to the topline announcement.

We previously placed comparator discontinuation rates from the semaglutide and tirzepatide programmes next to these figures. We have removed them for the same reason we removed the comparison table: no head-to-head trial exists, the trials differ in population, duration and escalation, and we could not re-verify those comparator percentages against a primary source.

After the Last Dose: Half-Life and the Gap in the Record

The earlier "When Do the Side Effects Subside?" section describes what happened during continued treatment and escalation. This section asks the opposite question: what happens after the last injection.

The trial record gives one measured pharmacokinetic figure. In the phase 1b multiple-ascending-dose trial in people with type 2 diabetes, the publication states that the pharmacokinetics of retatrutide "were dose proportional and its half-life was approximately 6 days" (Urva et al., Lancet, PMID 36354040). Retatrutide is investigational and has no approved product label.

Data past the last dose were collected but not reported in that shape. The registry record of the phase 2 obesity trial gives the adverse-event window as "Baseline Through End of Safety Follow-up (Up to 52 Weeks)" (NCT04881760). Its publication reports a 48-week treatment phase (PMID 37366315). The posted entries are cumulative counts per arm, not resolution curves. As of 2026-09-04, no completed study has reported the time required for individual side effects to resolve after a final retatrutide dose (PubMed search: "retatrutide AND (washout OR discontinuation OR cessation)"; ClinicalTrials.gov search: "retatrutide AND (withdrawal OR maintenance)").

The designs built around stopping measure weight, not symptom timing. SURMOUNT-4, a randomized withdrawal trial of tirzepatide, reported a mean percent weight change from week 36 to week 88 of -5.5% with continued tirzepatide against 14.0%, a regain, with placebo (Aronne et al., JAMA, PMID 38078870). The retatrutide counterpart is running and unreported: TRIUMPH-6 (NCT06859268), a phase 3b study listed as active and not recruiting, with an 80-week lead-in, a 36-week randomized phase in which one arm switches to placebo, and body weight at week 116 as the primary endpoint. That meta-regression measured weight, not appetite: a nonlinear analysis of six randomized GLP-1 receptor agonist trials estimated a weight-regain rate constant corresponding to a half-life of 23.0 weeks (95% CI 17.3 to 34.3) (Budini et al., EClinicalMedicine, PMID 41938838), covered in our weight regain article. Whether one person's appetite, reflux or energy settles in days or weeks is a clinical question the trial record does not answer.

Who the Trials Enrolled, and Who They Excluded

Every rate above belongs to a defined population. The published phase 2 trial enrolled adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition (PMID 37366315). Its exclusions for diabetes, recent cardiac events and uncontrolled hypertension are in Retatrutide, Heart Rate and HRV; the registry record adds an eGFR floor of 45 mL/min/1.73 m2, prior pancreatitis and active cancer within five years (NCT04881760, completed).

Phase 3 widened the population, each posting its own criteria:

• TRIUMPH-1 (NCT05929066, completed): BMI 30.0 or higher, or 27.0 or higher with hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease; diabetes mellitus excluded.
• TRIUMPH-2 (NCT05929079, completed): type 2 diabetes on stable treatment for at least 90 days, BMI 27.0 or higher; type 1 diabetes excluded.
• TRIUMPH-3 (NCT05882045, completed): BMI 35.0 or higher plus established cardiovascular disease: prior myocardial infarction, prior ischemic or hemorrhagic stroke or symptomatic peripheral arterial disease; acute myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina or congestive heart failure within 90 days before screening excluded.
• TRIUMPH-4 (NCT05931367, completed): BMI 27 or higher plus index knee pain and Kellgren-Lawrence grade 2 or 3 knee X-ray changes; diabetes mellitus excluded.
• TRANSCEND-T2D-1 (NCT06354660, completed): type 2 diabetes with HbA1c 7.0 to 9.5 percent, insulin-naive; NYHA class IV congestive heart failure, eGFR below 15 mL/min/1.73 m2 and known clinically significant gastric emptying abnormality excluded.

As of 2026-09-04, no completed study has reported retatrutide outcomes in polycystic ovary syndrome (PubMed search: "retatrutide AND (polycystic ovary syndrome OR PCOS)"; ClinicalTrials.gov search: "query.intr=retatrutide&query.cond=polycystic ovary syndrome"), in irritable bowel syndrome (PubMed search: "retatrutide AND (irritable bowel syndrome OR IBS)"; ClinicalTrials.gov search: "query.intr=retatrutide&query.cond=irritable bowel syndrome"), in hiatal hernia (PubMed search: "retatrutide AND hiatal hernia"; ClinicalTrials.gov search: "query.intr=retatrutide&query.cond=hiatal hernia") or in postural orthostatic tachycardia syndrome (PubMed search: "retatrutide AND (postural orthostatic tachycardia syndrome OR POTS)"; ClinicalTrials.gov search: "query.intr=retatrutide&query.cond=postural orthostatic tachycardia syndrome"). The phase 2 diabetes trial excluded "an autoimmune abnormality for example, lupus or rheumatoid arthritis" (NCT04867785, completed). A recruiting phase 2 trial separately excludes active autoimmune abnormality likely to require systemic steroids, plus tachyarrhythmia syndromes (NCT07467447). On rhythm questions the record is population level: the phase 2 publication reports heart-rate increases that "peaked at 24 weeks and declined thereafter" (PMID 37366315), not a measurement during exertion. Whether a diagnosis makes this investigational compound appropriate for a person is a clinical question, not answerable here.

Open Questions on Long-Term Safety

Since retatrutide is still in clinical development, several safety questions remain open. These are particularly relevant for ongoing research.

Hair Loss (Telogen Effluvium)

Reports of hair loss associated with incretin agonists are increasing, particularly with rapid weight loss. Telogen effluvium is frequently discussed as an explanation: metabolic stress and caloric restriction cause more hair follicles to enter the resting phase simultaneously. This would not be a direct pharmacological effect but a consequence of weight loss. Whether this occurs more frequently under retatrutide is not currently established.

Bone Density

Rapid weight loss can be associated with loss of bone mass. This effect is well documented regardless of the mechanism of weight loss, including after bariatric surgery. Specific data on bone density under retatrutide are not yet available. Given the substantial weight loss observed in studies, this remains a relevant research topic.

Muscle Mass

With any significant weight loss, a portion of lost mass is lean mass including muscle mass. Whether the glucagon receptor agonism of retatrutide influences this ratio has not been conclusively clarified. Reliable data from body composition analyses are still pending.

Thyroid

GLP-1 receptor agonists carry warnings regarding medullary thyroid carcinomas, based on animal studies in rodents. No extensively published long-term data on retatrutide are yet available to permit further reassurance. Accordingly, long-term endocrine monitoring remains part of ongoing and future studies.

Pancreatitis

Isolated cases of pancreatitis were reported in the studies, without a statistically significant increase over placebo. This corresponds to the profile of other incretin agonists. Monitoring of pancreatic markers (lipase, amylase) is routinely performed in clinical research.

Ongoing Studies: The TRIUMPH Programme

According to Lilly, the initial registrational TRIUMPH core programme comprised four global Phase 3 studies: TRIUMPH-1 through TRIUMPH-4. These studies cover chronic weight management and important comorbidities such as obstructive sleep apnoea and knee osteoarthritis. In addition, Lilly referenced further Phase 3 readouts in 2026. The safety profile of retatrutide will therefore only be reliably interpretable once the outstanding full publications and additional study reports become available.

Conclusions for Research

The safety profile of retatrutide resembles that of other incretin-based peptides in many respects, with gastrointestinal side effects as the most common category. The key points for research:

1. GI side effects are the central tolerability factor. In the trials they occurred mainly during the escalation phase, and the Phase 2 publication reports they were partially mitigated with a lower starting dose. That is an observation from supervised clinical trials, not a protocol suggestion.
2. Dysaesthesia is a notable signal in TRIUMPH-4. At up to 20.9% at 12 mg, it is relevant for further safety assessment but needs to be characterised in more detail.
3. Discontinuation in the retatrutide trials was dose-related. It ran roughly 6 to 16% in Phase 2 against 0% on placebo, and 12.2% (9 mg) and 18.2% (12 mg) against 4% on placebo in the TRIUMPH-4 topline. We do not rank this against other compounds, because no head-to-head trial exists. Without a results publication, the reasons behind the TRIUMPH-4 discontinuations cannot be independently interpreted.
4. Long-term data are still lacking. Questions on bone density, muscle mass, hair loss and endocrine safety can only be answered with longer follow-up.
5. Topline data represent only an interim status. The outstanding Phase 3 full publications are decisive for reliable safety conclusions.

Retatrutide is available as a research-grade peptide at PeptidesDirect. Further information on related peptides can be found on our product pages for semaglutide and tirzepatide.

---

Sources and further reading:

- Jastreboff AM et al. Retatrutide, a Triple-Hormone Receptor Agonist, for Obesity - A Phase 2 Trial. NEJM, 2023. PubMed: https://pubmed.ncbi.nlm.nih.gov/37366315/

- Eli Lilly. TRIUMPH-4 Topline Results, December 2025: https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html

- Eli Lilly FAQ with context and timeline of retatrutide updates: https://www.lilly.com/news/stories/what-to-know-about-retatrutide

- Abouelmagd AA, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings. 2025;38(3):291-303. DOI: https://doi.org/10.1080/08998280.2025.2456441

- Zhang Y, Zhang C, Gong X, et al. Effect of GLP-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis. European Journal of Medical Research, 2026. This open-access review is the source of the week-48 heart-rate figures quoted above, which it tabulates arm by arm. PubMed: https://pubmed.ncbi.nlm.nih.gov/41582189/

- ClinicalTrials.gov registry records with the posted eligibility criteria of the phase 3 program: TRIUMPH-1 https://clinicaltrials.gov/study/NCT05929066, TRIUMPH-2 https://clinicaltrials.gov/study/NCT05929079, TRIUMPH-3 https://clinicaltrials.gov/study/NCT05882045, TRIUMPH-4 https://clinicaltrials.gov/study/NCT05931367, TRANSCEND-T2D-1 https://clinicaltrials.gov/study/NCT06354660

- ClinicalTrials.gov registry records of the phase 2 trials: obesity https://clinicaltrials.gov/study/NCT04881760, type 2 diabetes https://clinicaltrials.gov/study/NCT04867785, and the currently recruiting phase 2 trial https://clinicaltrials.gov/study/NCT07467447

- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet, 2022. PubMed: https://pubmed.ncbi.nlm.nih.gov/36354040/

- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. PubMed: https://pubmed.ncbi.nlm.nih.gov/38078870/

- Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. EClinicalMedicine, 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/41938838/

- TRIUMPH-6 (NCT06859268), Eli Lilly phase 3b maintenance study of retatrutide, active and not recruiting, no results posted. ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06859268

- ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. NCT04881760, posted adverse-event tables: https://clinicaltrials.gov/study/NCT04881760?tab=results

- ClinicalTrials.gov. A Study of LY3437943 in Participants With Type 2 Diabetes. NCT04867785, posted adverse-event tables: https://clinicaltrials.gov/study/NCT04867785?tab=results

- ClinicalTrials.gov. A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction. NCT06313528, completed 26 August 2025, no results posted: https://clinicaltrials.gov/study/NCT06313528

- Narla S, Narla RR. Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies. Clinics in Dermatology, 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42562129/

- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 2022. PubMed: https://pubmed.ncbi.nlm.nih.gov/35985340/

- Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes, Obesity and Metabolism, 2016. PubMed: https://pubmed.ncbi.nlm.nih.gov/26434748/

- Heilbronn LK, de Jonge L, Frisard MI, et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA, 2006. PubMed: https://pubmed.ncbi.nlm.nih.gov/16595757/

- DailyMed label ZEPBOUND (tirzepatide), Eli Lilly, SPL version dated 28 August 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

- DailyMed label WEGOVY (semaglutide), Novo Nordisk, SPL version dated 18 June 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

- openFDA Drugs@FDA, query openfda.generic_name:"retatrutide", run 4 September 2026, no matching product: https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22retatrutide%22

- Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab, 2026 (online ahead of print). PubMed: https://pubmed.ncbi.nlm.nih.gov/42135195/

- Moller N. Ketone body, 3-hydroxybutyrate: minor metabolite - major medical manifestations. J Clin Endocrinol Metab, 2020 (review). PubMed: https://pubmed.ncbi.nlm.nih.gov/32525972/

- Tsunemi S, Nakamura Y, Yokota K, et al. Correlation between blood ketones and exhaled acetone measured with a semiconducting gas sensor. J Breath Res, 2022. PubMed: https://pubmed.ncbi.nlm.nih.gov/35868249/

- Baker LB, Wolfe AS. Physiological mechanisms determining eccrine sweat composition. European Journal of Applied Physiology, 2020. PubMed: https://pubmed.ncbi.nlm.nih.gov/32124007/

- Branine N. Online-sourced retatrutide complicating impending diabetic ketoacidosis in a patient with type 1 diabetes and concurrent Shigella gastroenteritis. Cureus, 2026 (single case report). PubMed: https://pubmed.ncbi.nlm.nih.gov/42669023/

- Eli Lilly and Company. A study of LY3437943 in participants who have obesity or are overweight (phase 2, completed, results posted; adverse-event table at a 5% reporting threshold). ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04881760

- Eli Lilly and Company. A study of retatrutide (LY3437943) on renal function in participants with overweight or obesity and chronic kidney disease (phase 2b, completed 21 October 2025, no results posted). ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05936151

- Eli Lilly and Company. A study to measure calorie consumption and usage in participants with obesity using LY3437943 (phase 1, completed 26 August 2025, no results posted). ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06313528

- Pasqualotto E, Ferreira ROM, Chavez MP, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 2024;24:100321. PubMed: https://pubmed.ncbi.nlm.nih.gov/39318607/

- Lu W, Wang S, Tang H, et al. Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database. European Psychiatry, 2025;68:e20. PubMed: https://pubmed.ncbi.nlm.nih.gov/39901452/

- ClinicalTrials.gov, NCT04881760 (phase 2 obesity trial), posted results, adverse event tables (reporting threshold 5% in any group): https://clinicaltrials.gov/study/NCT04881760?tab=results

- ClinicalTrials.gov, NCT04867785 (phase 2 type 2 diabetes trial), posted results, adverse event tables: https://clinicaltrials.gov/study/NCT04867785?tab=results

- WEGOVY (semaglutide) US prescribing information, adverse-reaction tables and Warnings 5.5, DailyMed SPL published 30 June 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

- ZEPBOUND (tirzepatide) US prescribing information, Table 1 adverse reactions, DailyMed SPL published 2 September 2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

- Urva S, O'Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab, 2023. PubMed: https://pubmed.ncbi.nlm.nih.gov/37311727/

- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab, 2020. PubMed: https://pubmed.ncbi.nlm.nih.gov/32519795/

- Little TJ, Feltrin KL, Horowitz M, et al. Dose-related effects of lauric acid on antropyloroduodenal motility, gastrointestinal hormone release, appetite, and energy intake in healthy men. Am J Physiol Regul Integr Comp Physiol, 2005. PubMed: https://pubmed.ncbi.nlm.nih.gov/15961531/

- Feinle C, O'Donovan D, Doran S, et al. Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol Gastrointest Liver Physiol, 2003. PubMed: https://pubmed.ncbi.nlm.nih.gov/12684211/

- Hiraide T, Suzuki Y, Yamamoto S, et al. Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet. J Health Popul Nutr, 2025. PubMed: https://pubmed.ncbi.nlm.nih.gov/41462404/

- Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clin Proc, 2025. PubMed: https://pubmed.ncbi.nlm.nih.gov/41324524/

This article is for informational purposes only for scientific research.

Disclaimer: FOR RESEARCH USE ONLY. All products from PeptidesDirect are intended exclusively for in vitro research and laboratory use. Not for human consumption. Not for in vivo applications. By purchasing you confirm that the products are not intended for ingestion or other application in humans.

Frequently Asked Questions

Related Products

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.